Obermatt
See Similar Stocks →

Climb Bio

NMQ:CLYM · US28658R1068
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings70
Price/Book47
Dividend Yield—
Revenue Growth—
Profit Growth78
Capital Growth48
TSR 52w98
Leverage93
Liquidity26
Refinancing86
Combined—
Analyst Opinions81
Pro Holdings27
Opinion Changes50
Market Pulse36

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2018
Employees43
Websiteclimbbio.com
ISINUS28658R1068
Last UpdateApr 2, 2026
Index & Theme
RheumatologyChronic DiseasesHematologyImmunologyBiotechnologyHealth CarePharmaceutical

Description

Climb Bio, Inc. operates as a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for the millions of patients living with immune-mediated diseases. The company has bu…

Similar Stocks

The companies this stock is ranked against.

Compare Climb Bio with its peers
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Design Therapeutics
NSQ:DSGN
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Equillium
NAQ:EQ
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
TG Therapeutics
NAQ:TGTX
77
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →